muramylnac-ala-isogln-lys-tripeptide and Fibrosarcoma
muramylnac-ala-isogln-lys-tripeptide has been researched along with Fibrosarcoma in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kurzman, ID; MacEwen, EG; Shi, F | 1 |
| Jarowenko, DG; Pellis, NR; Sigler, SC | 1 |
| Collins, M; Herberman, RB; Phillips, H; Schneider, M; Talmadge, JE; Wiltrout, RH | 1 |
Other Studies
3 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and Fibrosarcoma
| Article | Year |
|---|---|
In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antibodies, Monoclonal; Dogs; Doxorubicin; Drug Carriers; Fibrosarcoma; In Vitro Techniques; Leukocyte Count; Lipopolysaccharides; Liposomes; Monocytes; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1993 |
Muramyl tripeptide: an effective immunotherapy in the surgical setting for pediatric abdominal neoplasms.
Topics: Abdominal Neoplasms; Acetylmuramyl-Alanyl-Isoglutamine; Animals; Female; Fibrosarcoma; Immunity, Cellular; Immunotherapy; Liposomes; Macrophage Activation; Mice; Mice, Inbred C3H; Micelles; Neoplasm Seeding; Peritoneal Neoplasms; Sarcoma, Experimental; Time Factors | 1987 |
Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Cytotoxicity, Immunologic; Fibrosarcoma; Killer Cells, Natural; Liposomes; Liver; Lung; Lung Neoplasms; Lymphoma; Male; Mice; Mice, Inbred C3H; Phosphatidylethanolamines; Spleen | 1985 |